HomeCompareEMTRF vs MRK

EMTRF vs MRK: Dividend Comparison 2026

EMTRF yields 231.86% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EMTRF wins by $288.21M in total portfolio value
10 years
EMTRF
EMTRF
● Live price
231.86%
Share price
$0.86
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$288.27M
Annual income
$155,954,718.93
Full EMTRF calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — EMTRF vs MRK

📍 EMTRF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEMTRFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EMTRF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EMTRF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EMTRF
Annual income on $10K today (after 15% tax)
$19,707.86/yr
After 10yr DRIP, annual income (after tax)
$132,561,511.09/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, EMTRF beats the other by $132,553,182.68/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EMTRF + MRK for your $10,000?

EMTRF: 50%MRK: 50%
100% MRK50/50100% EMTRF
Portfolio after 10yr
$144.16M
Annual income
$77,982,258.54/yr
Blended yield
54.09%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

EMTRF
No analyst data
Altman Z
399.4
Piotroski
2/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EMTRF buys
0
MRK buys
0
No recent congressional trades found for EMTRF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEMTRFMRK
Forward yield231.86%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$288.27M$56.8K
Annual income after 10y$155,954,718.93$9,798.13
Total dividends collected$273.76M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: EMTRF vs MRK ($10,000, DRIP)

YearEMTRF PortfolioEMTRF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$33,886$23,185.72$11,206$366.19+$22.7KEMTRF
2$109,684$73,426.61$12,650$502.35+$97.0KEMTRF
3$339,487$222,125.05$14,407$694.19+$325.1KEMTRF
4$1,005,780$642,528.97$16,585$967.82+$989.2KEMTRF
5$2,855,237$1,779,051.76$19,342$1,363.89+$2.84MEMTRF
6$7,775,123$4,720,019.33$22,913$1,947.19+$7.75MEMTRF
7$20,331,652$12,012,271.08$27,662$2,823.89+$20.30MEMTRF
8$51,111,537$29,356,668.76$34,159$4,173.35+$51.08MEMTRF
9$123,660,779$68,971,434.58$43,337$6,308.80+$123.62MEMTRF
10$288,271,752$155,954,718.93$56,776$9,798.13+$288.21MEMTRF

EMTRF vs MRK: Complete Analysis 2026

EMTRFStock

Element 29 Resources Inc. acquires, explores for, evaluates, and develops mineral properties in Peru. The company primarily explores for copper, molybdenum, gold, silver, lead, zinc, and other deposits. Its flagship property is the Flor de Cobre project comprising seven mining concessions and two concession applications covering an area of approximately 1,927 hectares located in the Southern Peru. The company also holds 100% interests in the Elida project that includes 28 mining concessions covering an area of approximately 19,210 hectares located in the province of Ocros; the Pahuay Copper Skarn project covering an area of approximately 700 hectares located to the south of Lima; and Muñaorjo copper project covering an area of 1,000 hectares located in Peru. Element 29 Resources Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.

Full EMTRF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this EMTRF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EMTRF vs SCHDEMTRF vs JEPIEMTRF vs OEMTRF vs KOEMTRF vs MAINEMTRF vs JNJEMTRF vs ABBVEMTRF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.